Curis Inc. (CRIS) Shares Decline 2.5 % in 24‑Hour Trading Period
- Closing time: 12:39 PM Central Europe, Thursday 22 April 2026
- Current share price: USD 0.39
- Market capitalization: USD 950.6 k
- 24‑hour trading volume: USD 37.4 k
- Shares outstanding: 2.4 million
Curis Inc., a biotechnology firm listed on the Nasdaq, saw its shares fall 2.5 % during the 24‑hour period ending at 12:39 PM Central Europe on Thursday 22 April 2026. The stock is currently valued at approximately USD 0.39 per share. The company’s market capitalization stands at USD 950.6 k, with a total of 2.4 million shares available on public exchanges. Trading volume over the last 24 hours amounted to USD 37.4 k.
Since the end of the previous month, Curis shares have declined 61 %. The simple moving average over the last 200 days is USD 9.65. In the last 52 weeks, the highest price reached USD 33.6 on 24 October 2025, while the lowest price was USD 0.33 on 16 October 2026.
Regulatory Filings
A series of notices from the German Federal Gazette detail a net short position held by Squarepoint Ops LLC in New York. Each notice, dated between mid‑July and late July 2026, specifies the date of the position, the proportion of issued share capital involved, and confirms that the position is held by the same issuer. The filings collectively show a gradual increase in the short‑holding percentage over the observed period. No additional corporate actions or commentary were included in the releases.
Recent Performance of Related Stocks
| Ticker | 24‑Hour Change | Current Price | Market Cap |
|---|---|---|---|
| LESL (Leslie’s) | +17.74 % | USD 0.07 | USD 581 k |
| SBFM (Sunshine Biopharma) | –2.27 % | USD 0.22 | USD 853 k |
| SQFT (Presidio Property) | +1.13 % | USD 0.81 | USD 1.1 mn |
| VIVK (Vivakor) | –1.57 % | USD 1.26 | USD 1.1 mn |
| VBIO (Valion Bio) | –5.88 % | USD 1.12 | USD 1.1 mn |
Company Overview
Curis Inc. specializes in developing therapeutics for the regeneration and restoration of human tissues and organs. The company focuses on drug candidates for the treatment of human cancers and serves customers in the United States. Curis is listed on the Nasdaq, and its initial public offering took place on 1 August 2000. Further information can be found on the company’s website at www.curis.com .